Y-Intercept (HK)’s SpringWorks Therapeutics SWTX Stock Holding History

Y-Intercept (HK)’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-8,058	Closed	-$356K	–	2000
2025 Q1	$356K	Buy	+8,058	New	+$371K	0.02%	846
2024 Q1	–	Sell	-11,037	Closed	-$403K	–	1748
2023 Q4	$403K	Buy	+11,037	New	+$288K	0.04%	701
2023 Q1	–	Sell	-16,344	Closed	-$425K	–	1526
2022 Q4	$425K	Buy	16,344 +7,659	+88%	+$189K	0.06%	495
2022 Q3	$248K	Buy	+8,685	New	+$249K	0.02%	759

Other funds holding SWTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Y-Intercept (HK)'s SWTX Position: Q2 2025 in Review

Y-Intercept (HK) sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 8,058 shares — an estimated $356K sold.

Y-Intercept (HK) first reported a position in SWTX in Q3 2022 and held it in 4 quarters. The position peaked at $425K in Q4 2022. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

Y-Intercept (HK) reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
Y-Intercept (HK) sold 8,058 SpringWorks Therapeutics shares in Q2 2025, an estimated $356K.
Y-Intercept (HK) first reported a position in SpringWorks Therapeutics in Q3 2022 and held it in 4 quarters.
Y-Intercept (HK)'s SpringWorks Therapeutics position peaked at $425K in Q4 2022.
223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Y-Intercept (HK)'s 13F filing for Q2 2025, filed 1 Aug 2025.